Analysis of PET-CT to Identify Richter's Transformation in 167 Patients with Disease Progression Following Kinase Inhibitor Therapy
Anthony R. Mato(University of Pennsylvania), Jeffrey A. Jones(The Ohio State University), Lang Zhou(Qingdao University), Steven Coutré(Georgetown University), Paul M. Barr(University of Rochester Medical Center), Matthew S. Davids(Dana-Farber Cancer Institute), Herbert Eradat(University of Colorado Cancer Center), Michael Y. Choi(University of California San Diego), William G. Wierda(University of Maryland, Baltimore), Jalaja Potluri(AbbVie (United States)), Leonard T. Heffner, Bruce D. Cheson(National Cancer Institute), Maria Verdugo(AbbVie (United States)), Richard R. Furman(Cornell University)
Cited by 18
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k